	US 11,890,336 B2
	Francisella glycoconjugate vaccines
Brendan Wren, London (GB); Jon Cuccui, London (GB); and Madeleine Moule, Bryan, TX (US)
Assigned to London School of Hygiene and Tropical Medicine, London (GB)
Filed by London School of Hygiene and Tropical Medicine, London (GB)
Filed on Nov. 16, 2020, as Appl. No. 17/098,809.
Application 17/098,809 is a division of application No. 16/326,642, abandoned, previously published as PCT/GB2017/052653, filed on Sep. 11, 2017.
Claims priority of application No. 1615427 (GB), filed on Sep. 12, 2016.
Prior Publication US 2021/0069312 A1, Mar. 11, 2021
Int. Cl. A61K 39/00 (2006.01); A61K 39/02 (2006.01); A61K 47/64 (2017.01); A61P 31/04 (2006.01); C07K 14/195 (2006.01); C12N 15/74 (2006.01)

CPC A61K 39/0208 (2013.01) [A61K 47/646 (2017.08); A61P 31/04 (2018.01); C07K 14/195 (2013.01); C12N 15/74 (2013.01); A61K 2039/55566 (2013.01); A61K 2039/55572 (2013.01); A61K 2039/575 (2013.01); A61K 2039/6037 (2013.01); A61K 2039/6068 (2013.01); A61K 2039/70 (2013.01); C07K 2319/40 (2013.01)]

18 Claims

1. A vaccine or immunogenic composition, comprising:

a carrier polypeptide comprising at least 95% identity over the full length of the amino acid sequence of SEQ ID NO: 3 and

an O-antigen antigenic polysaccharide isolated from Francisella crosslinked to the carrier polypeptide,

wherein the O-antigen antigenic polysaccharide comprises 4)-α-D-GalNAcAN-(1-4)-α-D-GalNAcAN-(1-3)-β-D-GlcNAc-(1-2)-β-D-Qui4NFm-(1-), and

wherein GalNacAN is 2-acetomido-2-deoxy-O-D-galacturonamide, Qui4NFm is 4,6-dideoxy-4-formamido-D-glucose, and the reducing end group GlcNAc is N-acetyl glucosamine.